Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35

Nature Structural and Molecular Biology

Volumn 17, Issue 2, 2010, Pages 165-172

  Leung, Daisy W ^a   Prins, Kathleen C ^b   Borek, Dominika M ^c   Farahbakhsh, Mina ^a,d   Tufariello, Joann M ^b   Ramanan, Parameshwaran ^a   Nix, Jay C ^e   Helgeson, Luke A ^a,d   Otwinowski, Zbyszek ^c   Honzatko, Richard B ^a   Basler, Christopher F ^b   Amarasinghe, Gaya K ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Biochemistry Undergraduate Program   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; DOUBLE STRANDED RNA; EBOLA VIRAL PROTEIN 35; RETINOIC ACID INDUCIBLE PROTEIN I LIKE RECEPTOR; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GENE MUTATION; HYDROPHOBICITY; IMMUNE RESPONSE; IN VIVO STUDY; MOLECULAR RECOGNITION; MOLECULAR SENSOR; NONHUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; PROTEIN STRUCTURE;

BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DEAD-BOX RNA HELICASES; EBOLAVIRUS; IMMUNE EVASION; INTERFERONS; MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA, DOUBLE-STRANDED; RNA-BINDING PROTEINS; VIRAL REGULATORY AND ACCESSORY PROTEINS;

EBOLA VIRUS;

EID: 76349125544     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.1765     Document Type: Article

References (61)

1. Bosio, C.M., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188, 1630-1638 (2003).
2. Mahanty, S., et al. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312, 415-424 (2003).
3. Bray, M. & Geisbert, T.W. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol. 37, 1560-1566 (2005).
4. Baize, S., et al. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat. Med. 5, 423-426 (1999).
5. Feldmann, H., Wahl-Jensen, V., Jones, S.M. & Stroher, U. Ebola virus ecology: a continuing mystery. Trends Microbiol. 12, 433-437 (2004).
6. Matsukura, S., et al. Role of RIG-I, MDA-5, and PKR on the expression of infammatory chemokines induced by synthetic dsRNA in airway epithelial cells. Int. Arch. Allergy Immunol. 143 Suppl 1, 80-83 (2007).
7. Hausmann, S., Marq, J.B., Tapparel, C., Kolakofsky, D. & Garcin, D. RIG-I and dsRNA-induced IFN-β activation. PLoS One 3, e3965 (2008).
8. Saito, T. & Gale, M. Jr. Principles of intracellular viral recognition. Curr. Opin. Immunol. 19, 17-23 (2007).
9. Spiropoulou, C.F., et al. RIG-I activation inhibits ebolavirus replication. Virology 392, 11-15 (2009).
10. Schlee, M., et al. Approaching the RNA ligand for RIG-I? Immunol. Rev. 227, 66-74 (2009).
11. Schlee, M., et al. Recognition of 5′ triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 31, 25-34 (2009).
12. Yoneyama, M., et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat. Immunol. 5, 730-737 (2004).
13. Schmidt, A., et al. 5′-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc. Natl. Acad. Sci. USA 106, 12067-12072 (2009).
14. Li, X., et al. Structural basis of double-stranded RNA recognition by the RIG-I like receptor MDA5. Arch. Biochem. Biophys. 488, 23-33 (2009).
15. Basler, C.F., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77, 7945-7956 (2003).
16. Basler, C.F., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. USA 97, 12289-12294 (2000).
17. Cardenas, W.B., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits a/p interferon production induced by RIG-I signaling. J. Virol. 80, 5168-5178 (2006).
18. Habjan, M., et al. Processing of genome 5' termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS One 3, e2032 (2008).
19. Hartman, A.L., et al. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 82, 2699-2704 (2008).
20. Hartman, A.L., Dover, J.E., Towner, J.S. & Nichol, ST. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80, 6430-6440 (2006).
21. Hartman, A.L., Ling, L, Nichol, ST. & Hibberd, M.L. Whole-genome expression profling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 82, 5348-5358 (2008).
22. Hartman, A.L., Towner, J.S. & Nichol, ST. A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of infuenza A virus. Virology 328, 177-184 (2004).
23. Kash, J.C., et al. Global suppression of the host antiviral response by Ebola-and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80, 3009-3020 (2006).
24. Haasnoot, J., et al. The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3, e86 (2007).
25. Schumann, M., Gantke, T. & Muhlberger, E. Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 8993-8997 (2009).
26. Huang, Y., Xu, L, Sun, Y. & Nabel, G.J. The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modifcation of nucleoprotein. Mol. Cell 10, 307-316 (2002).
27. Shi, W., et al. A flovirus-unique region of Ebola virus nucleoprotein confers aberrant migration and mediates its incorporation into virions. J. Virol. 82, 6190-6199 (2008).
28. Johnson, R.F., McCarthy, S.E., Godlewski, P.J. & Harty, R.N. Ebola virus VP35-VP40 interaction is suffcient for packaging 3E-5E minigenome RNA into virus-like particles. J. Virol. 80, 5135-5144 (2006).
29. Noda, T., et al. Ebola virus VP40 drives the formation of virus-like flamentous particles along with G P. J. Virol. 76, 4855-4865 (2002).
30. Reid, S.P., Cardenas, W.B. & Basler, C.F. Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology 341, 179-189 (2005).
31. Basler, C.F. & Amarasinghe, G.K. Evasion of interferon responses by Ebola and Marburg viruses. J. Interferon Cytokine Res. 29, 511-520 (2009).
32. Leung, D.W., et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. USA 106, 411-416 (2009).
33. Prins, K.C., et al. Mutations abrogating VP35 interaction with dsRNA render Ebola virus avirulent in guinea pigs. J. Virol. (in the press).
34. Li, X., et al. The RIG-I-like receptor LGP2 recognizes the termini of double-stranded RNA. J. Biol. Chem. 284, 13881-13891 (2009).
35. Lawrence, M.C. & Colman, P.M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
36. Muhlberger, E., Weik, M., Volchkov, V.E., Klenk, H.D. & Becker, S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artifcial replication systems. J. Virol. 73, 2333-2342 (1999).
37. Pippig, D.A., et al. The regulatory domain of the RIG-I family ATPase LGP2 senses double-stranded RNA. Nucleic Acids Res. 37, 2014-2025 (2009).
38. Chang, T.H., et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modifcation machinery. PLoS Pathog. 5, e1000493 (2009).
39. Prins, K.C., Cardenas, W.B. & Basler, C.F. Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83, 3069-3077 (2009).
40. Kato, H., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
41. Saito, T. & Gale, M. Jr. Differential recognition of double-stranded RNA by RIG-I-like receptors in antiviral immunity. J. Exp. Med. 205, 1523-1527 (2008).
42. Nallagatla, S.R., et al. 5′-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science 318, 1455-1458 (2007).
43. Takahasi, K., et al. Solution structures of cytosolic RNA sensor MDA5 and LGP2 C-terminal domains: identifcation of the RNA recognition loop in RIG-I-like receptors. J. Biol. Chem. 284, 17465-17474 (2009).
44. Murali, A., et al. Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response. J. Biol. Chem. 283, 15825-15833 (2008).
45. Leung, D.W., et al. Expression, purifcation, crystallization and preliminary X-ray studies of the Ebola VP35 interferon inhibitory domain. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 65, 163-165 (2009).
46. McKenna, S.A., et al. Purifcation and characterization of transcribed RNAs using gel fltration chromatography. Nat. Protoc. 2, 3270-3277 (2007).
47. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscilation mode. Methods Enzymol. 276, 307-326 (1997).
48. Pfugrath, J.W. The fner things in X-ray diffraction data collection. Acta Crystallogr. D Biol. Crystallogr. 55, 1718-1725 (1999).
49. Collaborative Computational Project. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
50. Vagin, A.A. & Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022 (1997).
51. Read, R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57, 1373-1382 (2001).
52. Murshudov, G.N., Vagin, A.A. & Dodson, E.J. Refnement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
53. Lamzin, V.S. & Wilson, K.S. Automated refnement of protein models. Acta Crystallogr. D Biol. Crystallogr. 49, 129-147 (1993).
54. Perrakis, A., Sixma, T.K., Wilson, K.S. & Lamzin, V.S. wARP: improvement and extension of crystallographic phases by weighted averaging of multiple-refned dummy atomic models. Acta Crystallogr. D Biol. Crystallogr. 53, 448-455 (1997).
55. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
56. Painter, J. & Merritt, E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450 (2006).
57. Davis, I.W., et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375-W383 (2007).
58. Lee, B. & Richards, F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55, 379-400 (1971).
59. DeLano, W.L. The PyMOL Molecular Graphics System (DeLano Scientifc, San Carlos, California, USA, 2002).
60. Delaglio, F., et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293 (1995).
61. Johnson, B.A. Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol. Biol. 278, 313-352 (2004).